They also have an increased risk for thromboembolism .
Comparing with age-matched controls , the relative risk for stroke is increased 2- to 7-fold in patients with nonrheumatic atrial fibrillation ( 3 , 8 , 13 ) , and the absolute risk for stroke is between 1 % and 5 % per year , depending on clinical characteristics ( 3 , 12 , 14 - 16 ) .
Paroxysmal atrial fibrillation disrupts the lives of patients ( 17 ) , but this perception may not be associated with frequency or duration of symptoms .
Warfarin therapy affects quality of life because of frequent blood testing and recommendations for limiting some activities .
Data Synthesis Does Aggressive Rhythm Control Improve Mortality and Morbidity Compared with Rate Control ?
Atrial fibrillation is the most common type of arrhythmia in adults , accounting for about one third of hospitalizations for arrhythmia ( 1 ) .
The prevalence increases from less than 1 % in persons younger than 60 years of age to more than 8 % in those older than 80 years of age ( 2 - 6 ) .
The incidence ranges from 0.2 % per year for men 30 to 39 years of age to 2.3 % per year in men 80 to 89 years of age ( 7 , 8) .
The age-adjusted incidence for women is about half that of men ( 9 ) .
The cardiac conditions most commonly associated with atrial fibrillation are rheumatic mitral valve disease , coronary artery disease , congestive heart failure , and hypertension ( 8 , 10 ) .
Noncardiac causes include hyperthyroidism , hypoxic conditions , surgery , and alcohol intoxication .
A predisposing condition exists in more than 90 % of cases ( 5 , 11 , 12 ) ; the remaining cases have what is called lone atrial fibrillation .
Patients with atrial fibrillation frequently have symptoms of hemodynamic compromise , ranging from irregular palpitations to the more insidious feeling of malaise .
Little is known about the direct effects of antiarrhythmic therapy and rate-control therapy on quality of life .
The American College of Cardiology/American Heart Association/European Society of Cardiology Task Force on Clinical Guidelines for the Management of Atrial Fibrillation classified atrial fibrillation into 4 types ( 20 ) : first detected episode , paroxysmal ( terminates spontaneously ) , persistent ( electrical or pharmacologic termination necessary ) , and permanent ( resistant to electrical or pharmacologic conversion or accepted by the physician ) .
The purpose of this review was to summarize the evidence that was available during formulation of the guidelines developed by the American College of Physicians ( ACP ) and the American Academy of Family Physicians ( AAFP ) for management of adult patients with nonpostoperative atrial fibrillation .
Although the relative benefits and risks of rate versus rhythm control are of paramount importance in the management of atrial fibrillation , studies directly addressed this issue only recently .
Intravenous administration of diltiazem in the treatment of supraventricular tachyarrhythmias.
UNLABELLED The aim of the study was to investigate the efficacy of diltiazem bolus intravenous administration , compared to disopyramide , in the treatment of various types of paroxysmal supraventricular tachyarrhythmias . METHOD Fifty patients ( 23 males , 27 females , mean age 47.7 + /- 15.2 years ) with paroxysmal supraventricular tachyarrhythmia ( 20 with paroxysmal atrial tachycardia , 23 with paroxysmal atrial fibrillation and rapid ventricular response and 7 with atrial fluttering ) were studied . Diltiazem at a dose of 0.25 - 0.30 mg/kg BW or disopyramide at a dose of 50 mg were given bolus IV . If conversion of the arrhythmia to sinus rhythm could not be achieved with the initial drug , the alternate was given . The order of administration of the drugs was r and om , independent of the type of the arrhythmia . Before and during drug administration detailed clinical examination and frequent blood pressure ( BP ) measurements were performed . Twenty-four hour Holter monitoring was done in all patients , starting with the administration of the antiarrhythmic drug . RESULTS 1 ) Paroxysmal atrial tachycardia : diltiazem administration converted the arrhythmia to sinus rhythm in all patients while disopyramide in only 1 of 9 patients who received this drug . 2 ) Paroxysmal atrial fibrillation : disopyramide converted the arrhythmia in 5 patients without significant change in ventricular response in the others . Diltiazem did not convert the arrhythmia though it caused significant decrease in ventricular response ( < 100 bpm ) and in 1 patient an important bradycardia ( 45 bpm ) . 3 ) Atrial fluttering : disopyramide converted the arrhythmia to sinus rhythm in 1 patient without significant change in the ventricular response in the others . Diltiazem caused significant decrease in the ventricular response without conversion to sinus rhythm . During conversion to sinus rhythm an AV junctional rhythm of short duration ( < 1 min ) was noticed in 5 patients and a short pause ( < 2 sec ) with or without an initial premature contraction in the remaining 21 . Disopyramide administration was not associated with side effects .  Diltiazem administration cause small ( < 20 mm Hg ) , transient ( < 30 min ) decrease of BP without symptoms with the exception of the patient with bradycardia in whom the BP decrease was significant ( 90/60 from 160/80 mm Hg ) followed by intense symptoms which lasted for six hours . CONCLUSIONS Diltiazem administration is extremely effective in conversion of paroxysmal atrial tachycardia to sinus rhythm . In addition it retards ventricular response in patients with atrial fibrillation and fluttering . Compared to disopyramide these effects of diltiazem are more pronounced and clinical ly pertinent
They also have an increased risk for thromboembolism .
Comparing with age-matched controls , the relative risk for stroke is increased 2- to 7-fold in patients with nonrheumatic atrial fibrillation ( 3 , 8 , 13 ) , and the absolute risk for stroke is between 1 % and 5 % per year , depending on clinical characteristics ( 3 , 12 , 14 - 16 ) .
Paroxysmal atrial fibrillation disrupts the lives of patients ( 17 ) , but this perception may not be associated with frequency or duration of symptoms .
Warfarin therapy affects quality of life because of frequent blood testing and recommendations for limiting some activities .
Data Synthesis Does Aggressive Rhythm Control Improve Mortality and Morbidity Compared with Rate Control ?
Atrial fibrillation is the most common type of arrhythmia in adults , accounting for about one third of hospitalizations for arrhythmia ( 1 ) .
The prevalence increases from less than 1 % in persons younger than 60 years of age to more than 8 % in those older than 80 years of age ( 2 - 6 ) .
The incidence ranges from 0.2 % per year for men 30 to 39 years of age to 2.3 % per year in men 80 to 89 years of age ( 7 , 8) .
The age-adjusted incidence for women is about half that of men ( 9 ) .
The cardiac conditions most commonly associated with atrial fibrillation are rheumatic mitral valve disease , coronary artery disease , congestive heart failure , and hypertension ( 8 , 10 ) .
Noncardiac causes include hyperthyroidism , hypoxic conditions , surgery , and alcohol intoxication .
A predisposing condition exists in more than 90 % of cases ( 5 , 11 , 12 ) ; the remaining cases have what is called lone atrial fibrillation .
Patients with atrial fibrillation frequently have symptoms of hemodynamic compromise , ranging from irregular palpitations to the more insidious feeling of malaise .
Little is known about the direct effects of antiarrhythmic therapy and rate-control therapy on quality of life .
The American College of Cardiology/American Heart Association/European Society of Cardiology Task Force on Clinical Guidelines for the Management of Atrial Fibrillation classified atrial fibrillation into 4 types ( 20 ) : first detected episode , paroxysmal ( terminates spontaneously ) , persistent ( electrical or pharmacologic termination necessary ) , and permanent ( resistant to electrical or pharmacologic conversion or accepted by the physician ) .
The purpose of this review was to summarize the evidence that was available during formulation of the guidelines developed by the American College of Physicians ( ACP ) and the American Academy of Family Physicians ( AAFP ) for management of adult patients with nonpostoperative atrial fibrillation .
Although the relative benefits and risks of rate versus rhythm control are of paramount importance in the management of atrial fibrillation , studies directly addressed this issue only recently .